The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Subscribe To Our Newsletter & Stay Updated
